Other hedge funds have also recently modified their holdings of the company. Russell Investments Group Ltd. purchased a new stake in shares of Pharmerica Corporation during the fourth quarter worth about $845,000. Comerica Bank boosted its stake in shares of Pharmerica Corporation by 5.6% in the fourth quarter. Comerica Bank now owns 32,773 shares of the company’s stock worth $859,000 after buying an additional 1,728 shares during the last quarter. State Street Corp boosted its position in Pharmerica Corporation by 8.1% in the fourth quarter. State Street Corp now owns 756,145 shares of the company’s stock worth $19,020,000 after buying an additional 56,414 shares in the last quarter. Tudor Investment Corp Et Al bought a new position in Pharmerica Corporation during the fourth quarter worth $207,000. Finally, Guggenheim Capital LLC boosted its position in Pharmerica Corporation by 452.4% in the fourth quarter. Guggenheim Capital LLC now owns 141,519 shares of the company’s stock worth $3,559,000 after buying an additional 115,898 shares in the last quarter. Institutional investors and hedge funds own 92.75% of the company’s stock.
Parametric Portfolio Associates LLC boosted its position in Pharmerica Corporation (NYSE:PMC) by 3.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 73,850 shares of the company’s stock after buying an additional 2,422 shares during the period. Parametric Portfolio Associates LLC owned about 0.24% of Pharmerica Corporation worth $1,728,000 as of its most recent filing with the SEC.
Pharmerica Corporation (NYSE PMC) traded up 15.57% during trading on Wednesday, reaching $28.95. The company’s stock had a trading volume of 8,063,935 shares. Pharmerica Corporation has a 52-week low of $19.20 and a 52-week high of $28.95. The stock’s 50-day moving average is $25.81 and its 200 day moving average is $24.72. The firm has a market capitalization of $900.17 million, a price-to-earnings ratio of 43.21 and a beta of 0.92.
Pharmerica Corporation (NYSE:PMC) last issued its quarterly earnings data on Friday, August 4th. The company reported $0.47 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.47. Pharmerica Corporation had a return on equity of 11.03% and a net margin of 0.98%. The business had revenue of $592 million for the quarter, compared to the consensus estimate of $592.96 million. During the same period last year, the business earned $0.47 EPS. The firm’s revenue was up 13.9% compared to the same quarter last year. On average, analysts predict that Pharmerica Corporation will post $1.92 EPS for the current fiscal year.
PMC has been the subject of a number of analyst reports. Zacks Investment Research upgraded Pharmerica Corporation from a “sell” rating to a “hold” rating and set a $27.00 price target for the company in a report on Tuesday, May 16th. KeyCorp cut Pharmerica Corporation to an “overweight” rating in a report on Wednesday. BidaskClub cut Pharmerica Corporation from a “hold” rating to a “sell” rating in a report on Monday. Finally, ValuEngine cut Pharmerica Corporation from a “buy” rating to a “hold” rating in a report on Friday, June 2nd.
About Pharmerica Corporation